allergic rhinitis
Conditions
Interventions
Accelerated group:An accelerated dose increase was performed with Alog (dimite allergen preparation, house dust mite/dust mite: 50/50%)
Conventional group:Use Alog (dimite allergen preparation, house dust mite/dust mite: 50/50%) for regular dose escalation as per product instructions
Sponsors
Foshan Women and Children Hospital
Eligibility
Sex/Gender
All
Age
5 Years to 14 Years
Inclusion criteria
Inclusion criteria: 1.Signed informed consent; 2.Aged 5 to 14 years; 3.IgE-mediated moderate to severe allergic rhinitis or rhinoconjunctivitis (with or without allergic asthma) caused by house dust mite allergens; 4.Patients with allergic asthma must be classified as "well controlled" under GINA 2020.
Exclusion criteria
Exclusion criteria: 1.General criteria such as inability to understand and comply with research requirements, low expected compliance, mental retardation, etc.; 2.Immunotherapy criteria include previous AIT injection for anaphylactic shock and dust mite specific immunotherapy in recent 5 years, etc.; 3.Diseases and health status: such as Severe acute or chronic diseases, Autoimmune diseases, immune defects, Severe psychiatric and psychological disorders, etc.; 4.Medications: Use of ß-blockers (locally or systemically), ACE inhibitors, contraindication for use of adrenalin, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total adverse events/serious adverse events and the number, incidence, timing, type and intensity of adverse events/serious adverse events related to semi-depot house dust mite allergen extract; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in laboratory test values (hematology, clinical chemistry, and urinalysis) before and after treatment;Change of vital signs and lung function measured before and after the treatment phase;Tolerability;Asthma Control Score; | — |
Countries
China
Contacts
Public ContactBai Jun
Foshan Women and Children Hospital
Outcome results
None listed